how to put money into cryptocurrency Top People also ask

According to Siemens, digital business revenue has more than doubled this year, reaching 1.7 billion euros, exceeding the commitment in 2021 ahead of schedule.Laimei Pharmaceutical Co., Ltd.: The controlling shareholder intends to transfer 23.43% of the shares by agreement. Laimei Pharmaceutical announced that Zhongheng Group, the controlling shareholder, intends to transfer 247 million shares of the company's unrestricted tradable A shares by public solicitation of the transferee, accounting for 23.43% of the company's total share capital, and the transfer price is not less than 4.42 yuan/share. If the share transfer is completed, the controlling shareholder and actual controller of the company may change.South Korea's Seoul Composite Index rose to 1%.

Tongfu Microelectronics traded 2.24 million shares at a discount of 60.0768 million yuan today. Tongfu Microelectronics traded 2.24 million shares at a discount of 60.0768 million yuan today, accounting for 3.32% of the total turnover of the day, and the transaction price was 26.82 yuan, which was 9.97% lower than the market closing price of 29.79 yuan.Huichuan technology: the company has started to apply AI technology in the field of machine vision. Huichuan technology said at the performance briefing that in the field of AI: the company has started to apply AI technology in the field of machine vision, and the exploration in other fields will be carried out according to customer needs and industrial development. In the field of humanoid robots: the company is currently led by the product competitiveness center, and multi-departments cooperate to develop core components such as motors, drivers and actuator modules. The spin-off and listing of the company's subsidiary, United Power, is progressing steadily and is still in the stage of listing counseling.Yuncong Technology: "The R&D team of large-scale model agent products is basically dissolved" is all false information. Yuncong Technology said on the interactive platform that the company's R&D team is stable at present, and a rigorous and meticulous hierarchical division of labor system has been established for the research and development of large-scale model related products. The configuration of R&D echelon will be flexibly adjusted according to the continuous evolution of large model technology and the changes of market demand of agent products. The statements of "the No.1 position of the big model algorithm" and "the R&D team of the big model agent product is basically dissolved" mentioned in the question are false information, and the company reserves the right to pursue legal responsibility for this. The company has been unswervingly promoting the research and product development of large-scale model and agent-related technologies.

Yibin Paper: Terminate the issue of A shares to specific targets in 2022 and withdraw the application documents. Yibin Paper announced that the company held the 31st meeting of the 11th Board of Directors and the 22nd meeting of the 11th Board of Supervisors on December 12, 2024, and deliberated and passed the Proposal on Terminating the Issue of A shares to specific targets in 2022 and withdrawing the application documents. Considering the changes in market environment and policies, and considering the actual situation, the company decided to terminate the issuance of A shares to specific targets.Shan Ying International: It is proposed to raise the share repurchase price ceiling to 3 yuan/share. Shan Ying International (600567) announced on the evening of December 12 that it intends to adjust the share repurchase price ceiling from 2.34 yuan/share to 3 yuan/share.CITIC Securities: The resonance between supply and demand of medical beauty accelerates the space expansion, and the difference in operating ability promotes the evolution of the industry structure. CITIC Securities Research Report stated that the medical beauty industry has both medical and consumption attributes, and the medical attribute has strong product-driven characteristics, while the consumption attribute has high operating ability requirements. The medical beauty botulinum toxin track is also affected by the dual attributes of medicine and consumption: 1) The increase in penetration rate, the acceleration of compliance substitution and the extension of indications have brought about high demand for medical beauty botulinum toxin, and with the recent supply expansion, the industry scale has experienced high growth; 2) The iteration of product innovation is slow, brand barriers are created through marketing, doctors are empowered through direct sales, and control is strengthened to enhance product competitiveness. Recently, a variety of medical botulinum toxins in China have been approved, and the promotion of low-priced products is expected to push up the penetration rate, and enterprises with strong operational capabilities will enter the market or promote the evolution of the pattern.